Pfizer is at the forefront of thegene therapy space, with established collaborations, partnerships and acquisitions that bolster our pipeline, and distinct state-of-the-art manufacturing capabilities to bring this next generation of scientific innovation to patients living with rare diseases. We continue to advance key clinical development programs in hemophilia A and B, Duchenne muscular dystrophy and additional pre-clinical research programs. Pfizer currently hasplans to invest up to approximately $800 million at our Sanford and Durham, North Carolina, gene therapymanufacturing facilities. The goal is to expand capacity, strengthen capabilities and supply critical, potentially life-changing medicines by leveraging an in-vivo recombinant adeno-associated virus gene therapy technology platform for patients with rare diseases around the world.